Scholar Rock Holding Corp
Scholar Rock (Nasdaq: SRRK) is a global biopharmaceutical company developing therapies for spinal muscular atrophy (SMA) and other rare, severe neuromuscular diseases. Its proprietary platform generates monoclonal antibodies that selectively target inactive precursor forms of growth factors. The lead candidate,… From the company’s description.
In fiscal 2025, Scholar Rock Holding Corp reported a net loss of $377.94M. Operations used $300.04M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Scholar Rock Holding Corp does
In the company’s own words
Scholar Rock (Nasdaq: SRRK) is a global biopharmaceutical company developing therapies for spinal muscular atrophy (SMA) and other rare, severe neuromuscular diseases. Its proprietary platform generates monoclonal antibodies that selectively target inactive precursor forms of growth factors. The lead candidate, apitegromab, is an investigational anti-myostatin antibody being developed for children and adults with SMA and for people with facioscapulohumeral muscular dystrophy; the company is also developing a subcutaneous formulation and advancing SRK-439, another anti-myostatin antibody. Its early-stage programs include candidates for cancer, fibrotic diseases and iron-restricted anemia, for which it is seeking partners. Scholar Rock is preparing for potential commercialization of apitegromab and has established a U.S. customer-facing team of approximately 50 professionals, with European commercial development beginning in Germany. The company was founded by scientists whose discoveries underpin its platform. Its website is https://scholarrock.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1727196
- SIC
- 2836
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Scholar Rock Holding Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Scholar Rock Holding Corp · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Scholar Rock Holding Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Scholar Rock Holding Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Scholar Rock Holding Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Scholar Rock Holding Corp's last four quarterly filings that the numbers alone won't show?”